Primaquine in vivax malaria: an update and review on management issues

Malaria Journal

关键词: Primaquine;    Plasmodium vivax;    Vivax Malaria;    Prophylaxis;    Radical cure;   

DOI  :  10.1186/1475-2875-10-351

来源: DOAJ

【 摘 要 】

Abstract

Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.

【 授权许可】

Unknown